Bial - Portela C S.A.: all 139 studies

Page 1 of 2. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world TreatmentRecruitingNCT07145190
• Anti-epileptogenic Effects of Eslicarbazepine AcetateCompletedNCT06597084Phase 2Results posted
• OpiCapone Effect on Motor Fluctuations and pAiNCompletedNCT04986982Phase 4Results posted
• Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedNCT04316143Phase 2Results posted
• Dosage Form Proportionality of Opicapone To-Be-Marketed FormulationCompletedNCT02305329Phase 1Results posted
• Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of OpicaponeCompletedNCT02305316Phase 1Results posted
• Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy VolunteersCompletedNCT02305277Phase 1Results posted
• Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersCompletedNCT02305017Phase 1Results posted
• Food Effect and Dosage Form Proportionality Study of Eslicarbazepine AcetateCompletedNCT02288312Phase 1Results posted
• The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of WarfarinCompletedNCT02287415Phase 1Results posted
• Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine AcetateCompletedNCT02284880Phase 1Results posted
• Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and CarbamazepineCompletedNCT02284854Phase 1Results posted
• Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor FunctionCompletedNCT02284828Phase 1Results posted
• Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed FormulationCompletedNCT02283840Phase 1Results posted
• Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.CompletedNCT02283827Phase 1Results posted
• A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateCompletedNCT02283814Phase 1Results posted
• Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac RepolarizationCompletedNCT02283788Phase 1Results posted
• Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepineCompletedNCT02281591Phase 1Results posted
• An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093CompletedNCT02281526Phase 1Results posted
• Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.CompletedNCT02281448Phase 1Results posted
• An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093CompletedNCT02281422Phase 1Results posted
• Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093CompletedNCT02279667Phase 1Results posted
• Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its MetabolitesCompletedNCT02172755Phase 1Results posted
• The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of DigoxinCompletedNCT02172742Phase 1Results posted
• A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093CompletedNCT02171234Phase 1Results posted
• A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093CompletedNCT02171195Phase 1Results posted
• The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093CompletedNCT02170649Phase 1Results posted
• The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02170376Phase 1Results posted
• A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093CompletedNCT02170077Phase 2Results posted
• Pharmacokinetics, Efficacy and Tolerability of BIA 2-093CompletedNCT02170064Phase 2Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideCompletedNCT02169895Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169479Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideCompletedNCT02169466Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169453Phase 1Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedNCT02169440Phase 1Results posted
• An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and MetabolitesCompletedNCT02169427Phase 1Results posted
• Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02169414Phase 1Results posted
• Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.CompletedNCT02151994Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentCompletedNCT02101190Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsCompletedNCT02092168Phase 1Results posted
• Comparative Bioavailability Study of BIA 9-1067 25 mg CapsulesCompletedNCT02071823Phase 1Results posted
• Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067CompletedNCT02071810Phase 1Results posted
• Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative FlavoursCompletedNCT02021461Phase 2Results posted
• A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy VolunteersCompletedNCT01879345Phase 1Results posted
• A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy VolunteersCompletedNCT01879332Phase 1Results posted
• Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I DisorderCompletedNCT01825837Phase 2Results posted
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I DisorderTerminatedNCT01824602Phase 2Results posted
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I DisorderCompletedNCT01822678Phase 2Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With FibromyalgiaCompletedNCT01820585Phase 2Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With MigraineCompletedNCT01820559Phase 2Results posted
• Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedNCT01679002Phase 1Results posted
• Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy VolunteersCompletedNCT01678976Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedNCT01568073Phase 3Results posted
• Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedNCT01568047Phase 2Results posted
• A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067CompletedNCT01568034Phase 2Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideCompletedNCT01536366Phase 1Results posted
• Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideCompletedNCT01533116Phase 1Results posted
• Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaCompletedNCT01533077Phase 1Results posted
• Effect of Rasagiline on BIA 9-1067 PharmacokineticsCompletedNCT01532141Phase 1Results posted
• Effect of BIA 9-1067 on Rasagiline PharmacokineticsCompletedNCT01532128Phase 1Results posted
• Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset SeizuresCompletedNCT01527513Phase 2Results posted
• Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedNCT01520987Phase 1Results posted
• A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsCompletedNCT01520727Phase 1Results posted
• Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticCompletedNCT01519284Phase 1Results posted
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesCompletedNCT01515891Phase 1Results posted
• Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly PatientsCompletedNCT01422720Phase 3Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.CompletedNCT01227655Phase 3Results posted
• Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic PainTerminatedNCT01129960Phase 3Results posted
• Eslicarbazepine Acetate as Therapy in Post-Herpetic NeuralgiaTerminatedNCT01124097Phase 3Results posted
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00988429Phase 3Results posted
• Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in ChildrenCompletedNCT00988156Phase 3Results posted
• Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy SubjectsCompletedNCT00987558Phase 1Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic NeuralgiaCompletedNCT00981227Phase 2Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic NeuropathyCompletedNCT00980746Phase 2Results posted
• Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy VolunteersCompletedNCT00971295Phase 1Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial SeizuresCompletedNCT00957684Phase 3Results posted
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial EpilepsyCompletedNCT00957372Phase 3Results posted
• Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyCompletedNCT00957047Phase 3Results posted
• Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and OxcarbazepineCompletedNCT00900237Phase 1Results posted
• Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral ContraceptiveCompletedNCT00898560Phase 1Results posted
• Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE StudyNo longer availableNCT07522606
• REal-life ON PARKinson's - ITaly (REONPARK-IT)Active, not recruitingNCT07403799
• Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedNCT07173738Phase 1
• Safety and Efficacy of BIA 5-1058 in PAHCompletedNCT06009185Phase 2
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDActive, not recruitingNCT05819359Phase 2
• Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedNCT05220072Phase 1
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedNCT04994860Phase 1
• Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedNCT04994119Phase 1
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedNCT04991207Phase 1
• Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedNCT04991194Phase 1
• Absorption, Distribution, Metabolism and Excretion of BIA 5-1058CompletedNCT04991181Phase 1
• Effect of Food on BIA 5-1058CompletedNCT04991155Phase 1
• eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedNCT04990284Phase 4
• OpicApone Sleep dISorderCompletedNCT04986995Phase 4
• Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedNCT04978597Phase 3
• Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedNCT04675944Phase 1
• Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedNCT04265027Phase 1
• Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058CompletedNCT04069130Phase 1
• Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseCompletedNCT03959540
• Relative Bioavailability and Bioequivalence of OpicaponeCompletedNCT03820037Phase 1

← Bial - Portela C S.A. overview and focus areas